FDA Liver Injury Conference Another Chance To Inform Guidance Changes
This article was originally published in The Pink Sheet Daily
March event will look at best ways to detect and assess drug liver injury causation as agency mulls reopening the 2009 final guidance.
You may also be interested in...
Agency soliciting contractor to produce 37 drugs withdrawn because of liver injury; goal is developing better tools for evaluating compounds in the pipeline.
Agency officials, industry and academia contemplate a new approach to gauging drug-induced liver injury by using individual patients’ baseline liver enzyme measurements, a move that some say could eliminate problems with the use of the upper limit of normal and allow for the assessment of DILI in cases where there is underlying liver injury.
A March stakeholder conference is set to consider questions unresolved by the agency's two-year-old guidelines.